The proposed COST actions aims at fostering the development of the emerging field of epitranscriptomics in Europe. We believe that, by understanding the role of RNA modifications in physiology and pathology, novel and powerful disease biomarkers and drug targets could be identified 2017 – 2020
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok